Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtre
1.
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons ; : 85-90, 2012.
Article Dans Coréen | WPRIM | ID: wpr-785118
2.
Journal of the Korean Association of Oral and Maxillofacial Surgeons ; : 470-476, 2011.
Article Dans Coréen | WPRIM | ID: wpr-217790

Résumé

INTRODUCTION: The incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) has increased gradually in patients who have undergone surgical treatment for osteomyelitis. In this study, a retrospective analysis of BRONJ patients was carried out using the data of osteomyelitis patients treated surgically. MATERIALS AND METHODS: Osteomyelitis patients, who underwent curettage, sequestrectomy, saucerization or decortications, and partial mandibulectomy at Seoul National University Dental Hospital from 2004 to 2010 were enrolled in this study. The patients were classified and categorized into two groups based on the surgical records and progress notes. One group comprised of patients with osteomyelitis and osteoporosis, and the other group included patients with osteomyelitis only. The epidemiological data of the BRONJ patients was analyzed to identify any trend in the incidence of BRONJ in osteomyelitis patients. RESULTS: Among 200 patients who underwent surgical intervention for osteomyelitis, 64 (32.0%) were identified as having osteoporosis as the underlying disease. In these 64 patients, more than 81.3% had been prescribed bisphosphonates. Females were far more affected by BRONJ than males. The incidence of BRONJ also increased with age. The posterior part of the mandible was affected more frequently by BRONJ. CONCLUSION: Although the availability of potent antibiotics and increased oral hygiene care can reduce the overall incidence of osteomyelitis, BRONJ can increase the total incidence. To prevent BRONJ, it is recommended that an oral examination be performed before prescribing bisphosphonates. Moreover, the patients should be educated about the potential risks of dental procedures that might be causal factors for BRONJ. Furthermore, patient swho take bisphosphonates for the treatment of osteoporosis should undergo periodic follow up oral examinations to prevent BRONJ.


Sujets)
Femelle , Humains , Mâle , Antibactériens , Ostéonécrose de la mâchoire associée aux biphosphonates , Curetage , Diagnostic buccal , Diphosphonates , Incidence , Mâchoire , Mandibule , Hygiène buccodentaire , Ostéomyélite , Ostéonécrose , Ostéoporose , Études rétrospectives
5.
Journal of Korean Medical Science ; : 853-859, 2005.
Article Dans Anglais | WPRIM | ID: wpr-176537

Résumé

To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we performed staining for HBME-1, high molecular weight cytokeratin (HCK), CK 19, thyroid transcription factor-1 (TTF-1) and E-cadherin (E-CD) on 125 various types of thyroid carcinomas. The HBME-1 staining was strong and diffuse in follicular carcinoma (FC), papillary carcinoma (PC), and poorly differentiated carcinoma (PDC), while it was rare in undifferentiated carcinoma (UC) as well as in benign lesions. Strong, diffuse staining for CK19 and HCK was predominantly found in PC, and these markers were not much found in other carcinomas. TTF-1 uniformly stained the tumor cells of all cases of PC, FC and Hurthle cell carcinoma (HC) and 42% of the PDC, while there was only focal staining in one case of the UC. Compared to the strong, diffuse reactivity in the benign lesions, E-CD staining was noted in 67% of PC, 80% of FC, 83% of HC, 58% of PDC and none of the UC. These results suggest that HBME-1 may be a marker for well-differentiated carcinomas while CK19 and HCK are phenotypic markers for papillary carcinoma. The loss or reduced expression of TTF-1 and E-CD may be markers for dedifferentiation.


Sujets)
Humains , Cadhérines/métabolisme , Analyse de profil d'expression de gènes , Régulation de l'expression des gènes tumoraux , Immunohistochimie , Kératines/métabolisme , Protéines nucléaires/métabolisme , Tumeurs de la thyroïde/métabolisme , Facteurs de transcription/métabolisme , Marqueurs biologiques tumoraux/métabolisme
SÉLECTION CITATIONS
Détails de la recherche